INAVO120 trial shows inavolisib, palbociclib, and fulvestrant significantly improved overall survival in PIK3CA-mutant ...

The latest readout from INAVO120 marks the first time a PI3K-inhibiting targeted treatment has shown an overall survival advantage.

mutant-selective PI3Kα inhibitor, and a pair of EGFR inhibitors codenamed STX-721 and STX-241. The Boston, US-based biotech said that its priority at present is to accelerate the development of ...

This month's cover highlights the article Selective tubulin-binding drugs induce pericyte phenotype switching and anti-cancer immunity by Bo He, Ruth Ganss and colleagues. Eribulin is an anti-cancer ...

Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, ...

-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half of 2025, including mature single agent and initial combination data -- Expansion of the Company ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Gonadotropin injections used to stimulate ...